# US 2016/0354444 A1 · Compositions and methods for the treatment of sexual dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354444 A1
- Document ID: US20160354444A1
- Status: Published application
- Kind: A1
- Application number: 15/173,398
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2015-06-04
- Inventors: Vijaykumar Rajasekhar
- Web page: https://patentgrep.com/patent/US20160354444A1

## CPC

- A61K 38/2257: {Prolactin}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are pharmaceutical compositions for the treatment of sexual dysfunction in an individual. In some embodiments, the pharmaceutical composition includes a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine. In one embodiment, the amino acid is arginine. In one embodiment, the prolactin variant further comprises an N-terminal deletion. In one embodiment, the prolactin variant is conjugated to a H(OCH2CH2)nOH molecule (e.g., n equals any number from 1 to 6). In some embodiments, the pharmaceutical composition is delivered to the individual by a microneedle patch or an inhalable formulation.

## Claims

### Claim 1

A pharmaceutical composition for the treatment of sexual dysfunction in an individual, the pharmaceutical composition comprising a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amino acid is arginine.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the prolactin variant further comprises an N-terminal deletion.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the prolactin variant is conjugated to a H(OCH2CH2)nOH molecule, where n equals any number from one to six.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is delivered to the individual by a microneedle patch.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein administration of the prolactin variant effectively reduces an effect of 5 to 15 ng/mL of prolactin in the plasma of the individual.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an inhalable composition.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the inhalable composition has a concentration between 1,400 to 21,500 ng/mL of the prolactin variant.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the inhalable composition is a powder composition.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, further comprising one or more of lactose and sodium phosphate as a pharmaceutically acceptable excipient.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the sexual dysfunction comprises one or more of the following: erectile dysfunction, prolonged sexual refractory period, premature ejaculation, anorgasmia, decreased frequency or duration of orgasm, decreased sexual desire or libido, hypoactive sexual desire disorder, reduced penile erections, delayed ejaculation, sleepiness with orgasm or sexual activity, fatigue with orgasm or sexual activity, drowsiness with orgasm, and drowsiness with sexual activity.

### Claim 12

A pharmaceutical composition for the treatment of sexual dysfunction in an individual, the pharmaceutical composition comprising a prolactin suppressor.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the prolactin suppressor is a prolactin variant in which a glycine residue at position 129 is substituted with arginine.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the prolactin suppressor is conjugated to a H(OCH2CH2)nOH molecule, where n equals any number from 1 to 6.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition further comprises one or more of zinc or a PDE5 inhibitor.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the sexual dysfunction comprises one or more of the following: erectile dysfunction, prolonged sexual refractory period, premature ejaculation, anorgasmia, decreased frequency or duration of orgasm, decreased sexual desire or libido, hypoactive sexual desire disorder, reduced penile erections, delayed ejaculation, sleepiness with orgasm or sexual activity, fatigue with orgasm or sexual activity, drowsiness with orgasm, and drowsiness with sexual activity.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the prolactin suppressor comprises one or more of the following: prolactin variants, prolactin receptor antagonists, truncated prolactin receptors, prolactin receptor inhibitors, serum prolactin binding proteins, soluble isoforms of the prolactin receptor, zinc, dopamine agonists, prolactin antibodies, prolactin receptor antibodies, growth hormone, growth hormone variants, truncated growth hormone receptors, placental lactogen, placental lactogen variants, truncated lactogen receptors, choriomammotropin, proliferin, somatolactin, estrogen, estrogen variants, progesterone, and progesterone variants.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein the prolactin suppressor directly or indirectly binds a prolactin receptor.

### Claim 19 (depends on 12)

The pharmaceutical composition of claim 12, wherein the prolactin suppressor is a soluble form of a prolactin receptor isoform that results from alternative splicing of a prolactin receptor primary mRNA transcript from exon 7 to exon 11.

### Claim 20 (depends on 12)

The pharmaceutical composition of claim 12, wherein the prolactin suppressor comprises a mutation in one of a prolactin receptor activation domain and a prolactin receptor heterodimerization domain.
